Loading organizations...
Loading organizations...
Actuate Therapeutics: Clinical-stage biopharmaceutical company developing elraglusib for difficult-to-treat cancers via GSK-3β inhibition.
Founded in 2015 by Daniel Schmitt, Andrew Mazar, and Alan Kozikowski, Actuate Therapeutics is a clinical-stage biopharmaceutical company based in Fort Worth developing cancer therapies through the inhibition of Glycogen Synthase Kinase-3β. The firm utilizes technology licensed from Northwestern University and the University of Illinois Chicago for its lead candidate, elraglusib, which recently received Orphan Drug Designation from the FDA for metastatic pancreatic ductal adenocarcinoma. Operating as a pre-revenue enterprise with ten employees, the company has treated over 500 patients across multiple oncology indications in its ongoing clinical trials. Backed by institutional investors including Kairos Ventures and Bios Partners, the business previously secured a $22.7 million state grant from CPRIT. To further fund its proprietary therapeutics pipeline, the organization raised $22.4 million during its August 2024 initial public offering on the Nasdaq under the ticker symbol ACTU.
Actuate Therapeutics has raised $28.2M across 2 funding rounds.
Actuate Therapeutics has raised $28.2M in total across 2 funding rounds.
Actuate Therapeutics has raised $28.2M in total across 2 funding rounds.
Actuate Therapeutics's investors include Bios Partners, DEFTA Partners, Kairos Ventures, Tech Coast Angels.
Actuate Therapeutics has raised $28.2M across 2 funding rounds. Most recently, it raised $6.5M Series B in November 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 13, 2019 | $6.5M Series B | Bios Partners | DEFTA Partners, Kairos Ventures |
| May 17, 2019 | $21.7M Series B | Kairos Ventures | Bios Partners, DEFTA Partners, Tech Coast Angels |